![]() |
|
|
Vol. 302, Issue 2, 497-501, August 2002
Department of Pharmacology and Toxicology, University of Utah, Salt
Lake City, Utah
Recent studies demonstrated that vesicular dopamine (DA) uptake can be
rapidly altered in synaptic vesicles purified from the striata of
stimulant-treated rats. Specifically, a single administration of the
plasmalemmal DA transporter inhibitor, cocaine, or the DA
D2 agonist, quinpirole, increases vesicular DA uptake in
vesicles purified from the striata of treated rats. These effects of
cocaine are prevented by pretreatment with a D2, but not
D1, DA receptor antagonist. The purpose of the present
study was to characterize the effect of a mechanistically different
psychostimulant, methamphetamine (METH), on vesicular DA uptake.
Results demonstrated that a single administration of this DA-releasing
agent rapidly and reversibly decreased vesicular DA uptake. The
METH-related decrease in vesicular DA uptake was attenuated by
pretreatment with the D2 antagonist, eticlopride, but not
the D1 antagonist, SCH23390
(R-[+]-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine). Core body temperature did not contribute to the effects of METH on
vesicular DA uptake. Neither quinpirole nor cocaine increased vesicular
DA uptake when rats were concurrently treated with METH. These studies
provide further evidence that psychostimulants rapidly and
differentially modify vesicular DA uptake. In addition, these studies
demonstrate a complex role for D2 DA receptors in altering vesicular DA transport.
This article has been cited by other articles:
![]() |
J. G. Truong, D. G. Wilkins, J. Baudys, D. J. Crouch, K. L. Johnson-Davis, J. W. Gibb, G. R. Hanson, and A. E. Fleckenstein Age-Dependent Methamphetamine-Induced Alterations in Vesicular Monoamine Transporter-2 Function: Implications for Neurotoxicity J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1087 - 1092. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lotharius, J. Falsig, J. van Beek, S. Payne, R. Dringen, P. Brundin, and M. Leist Progressive Degeneration of Human Mesencephalic Neuron-Derived Cells Triggered by Dopamine-Dependent Oxidative Stress Is Dependent on the Mixed-Lineage Kinase Pathway J. Neurosci., July 6, 2005; 25(27): 6329 - 6342. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Johnson-Davis, J. G. Truong, A. E. Fleckenstein, and D. G. Wilkins Alterations in Vesicular Dopamine Uptake Contribute to Tolerance to the Neurotoxic Effects of Methamphetamine J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 578 - 586. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Nakajima, K. Yamada, T. Nagai, T. Uchiyama, Y. Miyamoto, T. Mamiya, J. He, A. Nitta, M. Mizuno, M. H. Tran, et al. Role of Tumor Necrosis Factor-{alpha} in Methamphetamine-Induced Drug Dependence and Neurotoxicity J. Neurosci., March 3, 2004; 24(9): 2212 - 2225. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Sandoval, E. L. Riddle, G. R. Hanson, and A. E. Fleckenstein Methylphenidate Alters Vesicular Monoamine Transport and Prevents Methamphetamine-Induced Dopaminergic Deficits J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1181 - 1187. [Abstract] [Full Text] [PDF] |
||||